Q3 FY2026 · ended Sep 30, 2026 · Revenue $17.40B, +10.3% YoY · Filed Nov 3, 2026
AbbVie Inc. (ABBV) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $17.4 billion and net income of $4.2 billion. Free cash flow was $7.3 billion. As of Sep 30, 2026 it held $11.2 billion in cash and investments and $0 in total debt.
Revenue
$17.40B
+10.3% vs year-ago quarter
Net income
$4.22B
+2167.7% vs year-ago quarter
Operating cash flow
$7.61B
+8.3% vs year-ago quarter
Free cash flow
$7.30B
+10.0% vs year-ago quarter
EPS
$2.37
+2270.0% vs year-ago quarter
Dividend per share
$1.73
+5.5% vs year-ago quarter
Shares outstanding
1.77B
+0.0% vs year-ago quarter
Net cash
$11.16B
Q3 FY2026
Operating margin
32.2%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABBV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- North Chicago, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1551152
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $17.4B | $17.0B | $15.0B | $16.6B | $15.8B |
| Operating income | $6.3B | $6.4B | $4.0B | $4.5B | $1.9B |
| Net income | $4.2B | $3.6B | $695.0M | $1.8B | $186.0M |
| Diluted EPS | $2.37 | $2.03 | $0.39 | $1.02 | $0.10 |
| Operating cash flow | $7.6B | $3.4B | $3.8B | $5.2B | $7.0B |
| Free cash flow | $7.3B | $3.1B | $3.6B | $4.9B | $6.6B |
| Total assets | $147.7B | $135.1B | $136.5B | $134.0B | $133.9B |
| Stockholders' equity | -$4.6B | -$5.9B | -$6.7B | -$3.3B | -$2.6B |
| Cash and investments | $11.2B | $6.8B | $9.7B | $5.5B | $6.0B |
| Total debt | $0 | $0 | $0 | $67.9B | $3.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Nov 2, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 30, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 3, 2026 | Sep 3, 2026 |
All 1006 AbbVie Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.